Introduction: Mortality in patients with cystic fibrosis-related diabetes (CFRD) is higher than
INTRODUCTION
Cystic fibrosis (CF) is a multi-organ disease caused by mutations in the CF transmembrane conductance regulator gene that which lead to ineffective clearance of secretions from epithelial surfaces [1] . The pancreas is one of the main organs affected. A large proportion of patients will require pancreatic enzyme replacement therapy for the damaged exocrine functions of their pancreas. According to the 2014 report of the UK Cystic Fibrosis Registry, 18.3% of UK patients with CF have a diagnosis of CF-related diabetes (CFRD) [2] . This percentage is likely to increase with increased longevity of patients with CF, as up to 47.5% of adult patients with CF have a significant glucose metabolism impairment [3] .
The annual mortality rate among patients with CF in the UK is 1.5% [2] , but in CF patients with a diagnosis of CFRD the mortality rate increases by threefold [4] . Insulin therapy has consequently been advocated to ameliorate the poor outcome associated with CFRD based on its proposed positive impact on the lung function of patients diagnosed with CFRD, as well as its ability to alleviate the rate of decline in pulmonary function tests (PFTs). Patients are occasionally started on insulin therapy in the absence of fasting hyperglycemia or at the impaired glucose tolerance stage when impaired first-phase insulin release causes high post-prandial glucose [5] . As well as impacting on PFTs, the reduction in postprandial glucose excursions with insulin therapy is thought to help increase body weight. This approach is not without risk as the use of insulin is associated with an increased rate of hypoglycemia [5] .
Previous studies have shown that hypoglycemia, hyperglycemia, and glucose variability are additional risk factors for mortality and morbidity in the general inpatient population with diabetes [6] [7] [8] . We are not aware of any published study looking at the impact of these glucometric parameters on inpatients with a diagnosis of CF. The aim of this study was, therefore, to investigate patterns, frequency, and trends of hypoglycemia in the insulin-treated CF population of the National Health Service Greater Glasgow and Clyde (NHSGGC). We also investigated the association between hypoglycemia, hyperglycemia, and glucose variability, with morbidity (as measured by readmission rates) and mortality.
METHODS
All patients with CF whose healthcare needs were provided by the NHSGGC Health Board and their Community Health Index were identified. Additionally, the proportion of measured CBG values that were within the hypoglycemic range during a nocturnal time period (2400-0600 hours) versus daytime (0600-2400 hours) was calculated and compared to that of the daytime period (0600-2400 hours).
Statistical analysis of data was performed using R, a statistical computing environment [9] . Survival analysis was analyzed using the Cox proportional hazards model, including age at admission and duration of admission as covariables. The Chi-square test was used to compare the number of CBG measurements that were \4 mmol/L as a proportion of all CBG measurements performed during the daytime and nocturnal time periods.
This study was conducted in accordance with the Declaration of Helsinki. Informed consent was not required for this study.
RESULTS
A total of 291 patients with CF whose healthcare was provided by the NHSGGC Health Board were identified. Of all patients with CF, 126 had one or more CBG readings performed during the period of analysis. We identified a total of 1014 admission episodes and 22,711 CBG measurements for this group. Of these 126 patients, 66 were recorded as both receiving insulin therapy and having been admitted during the period of investigation. These latter 66 patients were included in the analysis and their characteristics are described in Table 1 .
Hypoglycemia was common within the total CF inpatient population on insulin, with 1433 CBG values (6.3%) recorded within the hypoglycemic range across all admissions. The proportion of CBG measurements below the threshold for hypoglycemia in patients with CF on insulin therapy was higher during the nighttime (2400-0600; P\0.01; Fig. 1 ).
Of the 66 patients included in the study, 64 (97%) were readmitted or died following the index admission during the follow-up period. days for those without. The occurrence of hypoglycemia was associated with a significant difference in time to first readmission or death on the survival analysis, with age and admission duration as covariables (P = 0.03; Fig. 2 ).
There was no significant association between hyperglycemia and time to first readmission or 
DISCUSSION
Identified biochemical hypoglycemia occurs more frequently in the inpatient population with insulin-treated CFRD than in the wider inpatient population with diabetes. In this study, 6.1% of the CBG measurements were in the hypoglycemic range, compared to 4.1% in a general diabetic population studied using the same methodology [9] . The higher rate of hypoglycemia seen in this group is likely to be due to the insulin therapy which all patients entered into our study were receiving. Local standard practice consists of a basal bolus regime with basal and prandial insulin analogs, as guided by the CBG measurements. Hypoglycemia may also be more common in the CFRD group secondary to diminished exocrine pancreatic function, with malabsorption, loss of glucagon response, and with CFRD [10] . As with the general population with diabetes, hypoglycemia is more frequent during the nighttime [9] . This is potentially important as overnight CBG testing is often not part of routine diabetes management. It has previously been shown that a significant burden of nocturnal hypoglycemia is likely to be unrecorded secondary to the sporadic nature of overnight testing [9] . We have shown that hypoglycemia is associated with a significant increase in the rate of the composite endpoint of readmission and death over a 3.5-year follow-up period.
With only one death occurring before the first readmission in this group, this finding is driven mainly by the increased rate of readmission.
Hypoglycemia was associated with a non-significant increase in overall mortality. It is possible that episodes of hypoglycemia cause direct harm or predict a tendency for future deleterious hypoglycemic episodes causing adverse outcome. While no significant difference in available baseline characteristics or frequency of CBG testing were observed between those patients with and without hypoglycemia, it is likely that patients who are more ill and thereby readmitted more quickly have greater degrees of sepsis, liver disease, debility, and physiological derangement and are, therefore, more prone to hypoglycemia.
In our dataset, hyperglycemia and glucose variability did not show a significant association with readmission or mortality. In general, studies on diabetes inpatient populations have reported that hypoglycemia, hyperglycemia, and increased glucose variability are associated with excess morbidity and mortality [6] [7] [8] . It is likely that our dataset is underpowered to show any statistically significant increase in mortality associated with hypoglycemia, hyperglycemia, or glucose variability in this patient group.
Most of the hypoglycemic episodes were noted at the times when routine blood sugar monitoring was performed on the ward, which happens four times daily in our unit. This observation suggests that there may be a significant burden of hypoglycemia at other times of the day when CBG is not being tested.
As hypoglycemia has been shown to confers excess mortality in the general inpatient population with diabetes, this possibility may be of clinical importance [6, 7] . 
